Scribe Therapeutics Inc. (NASDAQ:SCTX – Get Free Report) Director Carl Gordon acquired 1,000,000 shares of the business’s stock in a transaction on Monday, July 27th. The shares were purchased at an average price of $15.00 per share, with a total value of $15,000,000.00. Following the completion of the purchase, the director owned 1,348,825 shares in the company, valued at $20,232,375. This represents a 286.68% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.
Scribe Therapeutics Price Performance
Shares of Scribe Therapeutics stock opened at $18.36 on Thursday. Scribe Therapeutics Inc. has a 12 month low of $17.31 and a 12 month high of $25.49.
Featured Articles
- Five stocks we like better than Scribe Therapeutics
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Scribe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scribe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
